Anthera Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported loss from operations was $9,255,000 against $14,579,000 a year ago. Net loss applicable to common stockholders was $9,673,000 or $0.73 basic and diluted per share against $15,092,000 or $2.84 basic and diluted per share a year ago. The decrease in net loss per basic and diluted share is primarily driven by reduced operating expense in 2017 as compared to 2016. For the year, the company reported loss from operations was $36,432,000 against $57,177,000 a year ago. Net loss applicable to common stockholders was $29,377,000 or $2.86 basic and diluted per share against $66,437,000 or $12.87 basic and diluted per share a year ago.